Pandemic Perspectives: NCATS Director Urges Rare Disease Community To Push Against Return To Clinical Trial Status Quo
Chris Austin argued the rare disease community deserves the same “movement of heaven and earth” mentality as was employed for COVID-19.
You may also be interested in...
Decentralized Trials Ease Enrollment In Rare Disease Studies
Panel discussion illustrated how decentralized approaches can expand the possibilities of studies in rare diseases, such as cancers with rare genomic alterations.
US Needed Simple Pragmatic COVID-19 Trial For Repurposing Candidates, Woodcock Says
One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.
After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products
Stephen Hahn also said the expedited approval process could be even more efficient.